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Background: Laboratory investigations on diabetes mellitus (DM) have employed various animal models. Alloxan, a 
β-cell toxin, has widely been used to induce DM in animals. The current study reports peculiar glycemic patterns 
during alloxan DM induction. 
Method: Thirty eight, six-month old Sprague Dawley rats were assigned to two groups: control (n=14) and 
experimental (n=24). Alloxan (125 mg/kg) was administered intraperitoneally to the experimental group, and an 
equal volume of normal saline to the control. Using a glucometer, fasting blood glucose (FBG) levels were assessed on 
days 0, 3, 6, 13, 20 and 27. 
Results: At day 3, FBG levels were higher in the experimental group (19.26±1.77 vs. 3.21±0.04 mmol/l, p<0.01). 
Thereafter, FBG levels in the experimental group reduced gradually till day 27, though remaining higher than the 
control (7.59±0.86 vs. 3.22±0.13 mmol/l, p<0.01). The FBG levels in the control oscillated between 3.14±0.04 and 
3.26±0.05 mmol/l. Out of the 24 rats administered with alloxan, only 10 were diabetic at day 27. 
Conclusion: Induction of diabetes in rats using alloxan (125mg/kg) leads to variability in glucose levels. A number of 
animals greater than required may be necessary to accommodate failed diabetes induction. Follow-up for at least one 
month is necessary before confirming induction. 
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1. Introduction 
Animals are commonly used for experimentation in 
academic and research institutions (Kimwele et al, 
2011). The reliability of a study is partly determined by 
the animal model used. The researcher must therefore 
have a fine understanding of animal models when 
designing animal studies. The current study focuses on 
animal models used in investigating diabetes mellitus 
(DM), and its management. These animal models differ 
significantly and no single one has been reported to 
accurately represent the essential pattern of type 2 DM 
in humans, in whom the disease is often preceded by 
obesity and various molecular changes. Animal models 
are developed by techniques such as pancreatectomy, 
chemical induction, genetic engineering, molecular 
biology and islet cell transplantation (Junod et al, 1969; 
Lenzen et al, 1988; Lanza et al, 1999; Rees and Alcolado, 
2005; Frode and Medeiros, 2008). 
Advances in genetic engineering have led to breeding of 
specific animal strains which are susceptible to 
development of type 1 and 2 DM. These include the 
‘non-obese diabetic mouse’ and ‘bio-breeding rat’ for 
type 1 DM (Rees and Alcolado, 2005). Molecular 
biological techniques such as gene targeting and 
transgenic transfer have also been used. Animal models 
with specific gene alterations or with modified genes 
incorporated within their genome have been developed 
(Frode and Medeiros, 2008). However, commonly used 
genetic models deviate from human type 2 DM, because 
they contain mutations which are rare in human type 2 
DM (Coleman, 1978; Surwit et al, 1984; Kuhn et al, 
1987). Islet cell transplantation studies have also been 
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conducted in animal models, notably dogs and rodents 
(Lanza et al, 1999). 
In the majority of studies, chemical-induced diabetes 
models have been utilized (Frode and Medeiros, 2008). 
Such chemicals include alloxan (Lenzen, 2008), and 
streptozotocin (Junod et al, 1969). As at 2010, 
streptozotocin had reportedly been used in 69% of 
chemical-induced diabetes animal models, whereas 
alloxan was the second most commonly used chemical 
at 31% (Etuk, 2010).  
Alloxan is a urea derivative which causes selective 
necrosis of the pancreatic islet β-cells (Etuk, 2010). It is 
used experimentally to induce type 2 DM in animals 
such as rabbits, rats, mice and dogs. The experimental 
dose of the drug needs careful consideration in order to 
avoid excessive pancreatic tissue damage. The most 
frequently used intravenous dose of alloxan in rats is 65 
mg/kg, but its effective dose must be higher when it is 
administered intraperitoneally or subcutaneously 
(Antia et al, 2005). With the rising use of alloxan-
induced DM models, different dosages and different 
methods of inducing diabetes have been reported. 
Though most methods have demonstrated success, a 
handful have reported failed induction or variation in 
blood glucose following alloxan administration (Etuk, 
2010). The current study was thus carried out to assess 
the pattern of blood glucose following intraperitoneal 
administration of alloxan (125 mg/kg).  
 
2. Materials and Methods 
2.1 Study animals 
Thirty eight (38), six month old female Sprague Dawley 
rats weighing between 200 - 250 g were obtained from 
the Biochemistry animal laboratory, University of 
Nairobi. The animals were then housed in plastic cages 
in the animal house, Department of Medical Physiology, 
University of Nairobi, where a twelve hour light/dark 
cycle was maintained. The animals were fed on 
commercial pellets from a local supplier (Unga Feeds 
Ltd). Water was provided ad libitum. The rats were 
randomly assigned to control (n = 14) and experimental 
(n = 24) groups. The animals were allowed a 15 day 
acclimatization period after which baseline blood 
glucose and body weights were taken.  Thereafter, 
diabetes was induced on the experimental group using 
alloxan (125 mg/kg), while the control group received 
an equal volume of normal saline.  
2.2 Induction of diabetes mellitus 
The experimental animals were fasted for 16 hours 
before inducing DM. The animals were intraperitoneally 
injected with a single dose of alloxan (125 mg/kg), 
dissolved in 10% sodium chloride (Lenzen et al, 1988; 
Reyes et al, 2006; Lenzen, 2008). The alloxan was 
obtained from the Department of Medical Physiology 
and stored at 4 °C. The blood glucose levels were 
assessed on days 0, 3 and 6 following administration of 
alloxan. Thereafter, the animals were followed up for 3 
weeks with a weekly assessment of the blood glucose 
levels. The blood sample was obtained by sequential 
snipping of the tail (Fluttert et al, 2000). A glucometer 
(On Call® Plus, Acon Industries, Inc. 4108, San Diego, 
USA) was used to measure the blood glucose levels. 
Animals were considered diabetic if fasting blood 
glucose (FBG) level was above 7.1 mmol/l (Kwanghee et 
al, 2009). 
2.3 Ethical considerations 
The study protocol was approved by the Postgraduate 
Research Committee, Department of Medical 
Physiology, University of Nairobi. Animals were handled 
in accordance with the guidelines of the US National 
Research Council for the care and use of laboratory 
animals (National Academy Press, 1996). 
2.4 Data and statistical analysis 
Data were expressed as mean ± standard error of mean 
(SEM). Student’s t-test was employed to test statistical 
significance using SPSS Version 16.0. Significance levels 
were set at p < 0.05. 
 
3. Results 
Baseline FBG levels (day 0) were 3.06 ± 0.16 mmol/l 
and 3.24 ± 0.05 mmol/l in the experimental and control 
groups respectively. However,  the FBG level increased 
significantly in the experimental group (19.26 ± 1.77 vs. 
3.21 ± 0.04 mmol/l, p < 0.01) at day 3.  Thereafter, the 
FBG level in the experimental group reduced gradually 
till day 27, though still remaining higher than the 
control group (7.59 ± 0.86 vs. 3.22 ± 0.13 mmol/l, p < 
0.01). On the other hand, the FBG levels in the control 
group oscillated between 3.14 ± 0.04 mmol/l and 3.26 ± 
0.05 mmol/l for the duration of the study (Figure 1). 
Of the 24 experimental rats, four (16.67%) maintained 
normal blood glucose levels whereas 2 (8.33%) became 
glucose intolerant at day 6. Two rats (8.33%) achieved 
high glucose levels (> 30 mmol/l) at day 6 and died 
before day 27 (Table 1). Sixteen (66.67%) rats were 
‘diabetic’ at day 6, though one of these died before day 
27. Five (5) of the sixteen (16) rats recovered and 
became normoglycemic by day 27. Thus, of the 24 rats 
administered with alloxan, only 10 had successfully 
induced diabetes by day 27. On the other hand, all 
control rats (n=14) were alive and normoglycemic at 
day 27. 
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Figure 1: Effect of Alloxan on Fasting Blood Glucose level in rats (error bars ± SEM) 
 
Table 1: Glycemic and Death outcomes of rats following alloxan administration 
FBG at day 6 Number of rats Outcome at day 27 
Normal (3.2 ≤ x ≤ 6.0) 4 Alive 
Glucose intolerant (6.1 ≤ x ≤ 7.0) 2 Alive 
Diabetes mellitus(DM) (7.1 ≤ x ≥ 10) 3 Alive 
DM (10.1 ≤ x ≥ 20) 7 Alive 
DM (20.1 ≤ x ≥ 30) 6 5 alive, 1 died 
DM (> 30) 2 Died 
FBG, Fasting blood glucose; DM, Diabetes mellitus 
 
4. Discussion 
Alloxan is a known β-cell toxin that has widely been 
used in inducing DM (Lenzen et al 1988). Effects of 
alloxan (125 mg/kg) noted in the present study were: 
elevation of blood glucose levels to values still within 
the normal range, induction of glucose intolerance and 
ultimately induction of DM. This variation in response 
to the same dose of alloxan (125 mg/kg), demonstrates 
inter-individual dissimilarity among the rats with 
respect to resistance to the diabetogenic effect of 
alloxan. Such dissimilarity within a species may 
demonstrate cytological variation in the number and 
properties of β-cells. This may partly explain the varied 
response to similar environmental conditions in the 
development of DM among the general population. 
Besides the varied response, these results corroborate 
previous findings on the role of alloxan in the 
destruction of β-cells, thereby reducing pancreatic 
ability to secrete insulin (Lenzen, 2008). 
Of the twenty four (24) experimental rats, only 16 
(66.7%) were ‘diabetic’ at day 6, a number that later fell 
to 10 (41.7%) by the end of the induction period (day 
27). This was probably due to the recovery of partially 
destroyed β-cells. This gradual decrease in blood 
glucose levels in the experimental group could also be 
due to hormones counter regulatory to hyperglycaemia 
(Gelfand et al, 1984). In administering alloxan to induce 
DM, it is thus prudent to begin with a larger number of 
animals so as to take care of such variation. 
Furthermore, it is appropriate to follow up the animals 
for up to a month before any experimentation, to 
account for possible β-cell recovery.  
Several mechanisms have been proposed to explain the 
diabetogenic effect of alloxan. Alloxan induces the 
formation of reactive oxygen species (superoxide 
radicals, hydrogen peroxide and hydroxyl radicals) 
which mediate cellular damage (Lenzen, 2008). This 
cellular damage may in addition induce auto-immune 
reactions against the β-cells. Secondly, alloxan disrupts 
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the formation of microtubules as well as destroying 
those already formed (Schmidt et al, 1990). Thirdly, 
alloxan is thought to inhibit the enzyme O-linked N-
acetyl glucosamine transferase (Konrad et al, 2002), 
which is very abundant in the β-cells and catalyzes 
protein O-glycosylation. 
Alloxan and streptozotocin produce diabetes mellitus 
by selectively destroying pancreatic β-cells, and thus 
cause type 1 diabetes (Rakieten et al, 1963; Wilson et al, 
1984). Type 2 diabetes can be induced with these drugs 
by manipulating the dosages and timings of 
administration to destroy only a portion of β-cells 
(Portha et al, 1989; Serradas et al, 1991; Beppu et al, 
1993). These animal models, however, conceptually 
deviate from the pattern of type 2 DM in humans, in 
whom the disease is often preceded by obesity. 
Furthermore, insulin resistance in humans is a complex 
process that involves several mediators and other 
mechanisms outside the pancreas. In addition, rats have 
dissimilar pancreatic islet β-cell pathology compared to 
humans. This has implications since β-cell destruction is 
crucial in the development and progression of DM.  
The use of alloxan has been demonstrated to produce 
similar results in both female and male Sprague Dawley 
rats (Bernard, 1980). Furthermore, young animals have 
been reported to cope better than old animals with 
alloxan-induced stress (Bernard, 1980). The relatively 
old age of the animals used (6 months old) in the 
current study could have partly contributed to the 
deaths observed. In addition, it is known that the 
experimental dose of alloxan must be carefully selected 
to avoid excessive pancreatic tissue damage. As multiple 
methods and dosages of alloxan continue to be used for 
DM induction, we recommend their standardization for 
ease of replication. 
 
5.0 Conclusion 
Induction of diabetes in rats using alloxan (125 mg/kg) 
leads to variability in glucose levels. A larger number of 
animals may be required during administration of 
alloxan to take care of variation in DM induction. A 
follow-up period of up to one month may be necessary 
before confirming diabetes induction. 
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